The expression of prostaglandins-related genes in erythrocytes of broiler chicken responds to thiram-induced tibial dyschondroplasia and recombinant glutathione-S-transferase A3 protein.

Tibial dyschondroplasia (TD) is a type of bone deformity found in fast-growing chickens, which induce inflammatory responses. Prostaglandins (PGs) implicate in bone formation and bone resorption, associated with inflammation in an autocrine/paracrine manner. This study used qRT-PCR and immunohistochemistry analysis to identify the expression patterns of PG-related genes in the erythrocytes of broiler chickens and explore the effects of thiram-induced TD and the recombinant glutathione-S-transferase A3 (rGSTA3) protein on the expression of PG-related genes: GSTA3, cyclooxygenase 2 (COX-2), prostaglandin D2 synthase (PTGDS), prostaglandin E synthase (PTGES), prostaglandin E2 receptor (PTGER) 3, PTGER4 and prostaglandin reductase 1 (PTGR1). Interestingly, the results showed that these seven PG-related genes expression was identified in the erythrocytes of broiler chicken, and thiram-induced TD suppressed the expression of these PG-related genes in the initial stage of TD and promoted their expression in TD recovery. These findings demonstrated that the immunoregulatory function of erythrocytes can be inhibited in the early stage of TD and promoted in the recovery stage by modulating the expression of PG-related genes. Further, the rGSTA3 protein can modulate the expression of PG-related genes in erythrocytes and participate in the recovery of TD.

Activation of cannabinoid receptor CB2 regulates osteogenic and osteoclastogenic gene expression in human periodontal ligament cells.

BACKGROUND AND OBJECTIVE: Cannabinoid receptor CB2, expressed in osteoblasts and osteoclasts, plays a crucial role in the regulation of bone metabolism. Since periodontal ligament (PDL) cells can differentiate into osteoblasts, this study was undertaken to investigate CB2 expression and the effect of CB2 activation on osteogenic differentiation of PDL cells. MATERIAL AND METHODS: Human PDL (hPDL) cells were obtained from extracted teeth of periodontally healthy subjects. Expression of CB2 was observed in hPDL cells by RT-PCR, Western blotting and immunofluorescence assay. Then hPDL cells were treated with a CB2-specific agonist, HU-308 (10(-7) m), for 12, 24, 48 or 72 h. The mRNA expressions of osteogenic genes, such as runt-related transcription factor 2 (Runx2), bone sialoprotein (BSP), osteopontin (OPN), alkaline phosphatase (ALP), osteocalcin (OC) and collagen type I (COL I), and osteoclastogenic genes, including osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL), were examined using quantitative real-time PCR analysis. A mineralization assay was performed in hPDL cells in mineralization conditions with or without HU-308. RESULTS: Expression of CB2 mRNA and protein was detected in hPDL cells. HU-308 enhanced the mRNA levels of the above osteogenic genes. Expression of the OPG gene was up-regulated, whereas RANKL gene expression was down-regulated, contributing to the elevated OPG/RANKL ratio. Accelerated mineralization was observed in hPDL cells in mineralization conditions with HU-308. CONCLUSION: Our findings demonstrate that activation of CB2 is able to enhance osteogenic differentiation of hPDL cells and potentially create a favorable osteogenic microenvironment. This implies that CB2 might play an important role in alveolar bone metabolism.

[A Dutch family with the hereditary periodic fever or tumour necrosis factor receptor-associated periodic syndrome (TRAPS)]. / Een nederlandse familie met het erfelijke periodieke koortssyndroom 'tumornecrosisfactor receptor-associated periodic syndrome' (TRAPS).

A 9-month-old girl was referred to the paediatrician because of fever of unknown origin. Since the age of 4 years she had recurrent attacks of muscle, joint and abdominal pain, in addition to periodic fever. Her sister and her mother had similar symptoms. The tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) was suspected and confirmed by DNA analysis. Several members of the extended family were carriers of the same mutation. In patients with recurrent unexplained periods offever in combination with myalgia, arthralgia and abdominal pain, and in whom these symptoms also occur in members of the family, TRAPS should be considered as the cause. Glucocorticosteroids and etanercept, a TNF-receptor antagonist, may be effective in the treatment of attacks. Early recognition of this syndrome is important because of the risk of developing amyloidosis.